# Talia Golan

Source: https://onco.cc/people/talia-golan/  
OnCo record `talia-golan` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers.

## Summary

Talia Golan was principal investigator and first author of POLO, which showed maintenance olaparib nearly doubles progression-free survival in germline BRCA-mutant metastatic pancreatic cancer after platinum chemotherapy, the first targeted therapy approval in the disease. She directs the pancreatic cancer centre at Sheba and works on organoid-guided therapy and DNA damage response combinations.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: pancreatic; parp; brca
- Role: Director, Pancreatic Cancer Center, Sheba Medical Center
- Specialisms: Pancreatic cancer; BRCA-associated cancer; PARP inhibitors; Precision oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Golan%20T%5BAuthor%5D%20pancreatic%20olaparib

## Connected records

- cancers: [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Patient-derived organoids](https://onco.cc/technologies/organoids/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [Sheba Medical Center](https://onco.cc/institutions/sheba/)
- trials: [POLO](https://onco.cc/trials/polo/)
- key papers: [Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers](https://onco.cc/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/), [Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium](https://onco.cc/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/), [Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/), [POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer](https://onco.cc/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/), [POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer](https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/), [Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers](https://onco.cc/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/talia-golan.json